Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models

Molecular Cancer Therapeutics

Volumn 10, Issue 6, 2011, Pages 1072-1081

  Sharkey, Robert M ^a   Karacay, Habibe ^a   Govindan, Serengulam V ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CLIVATUZUMAB TETRAXETAN Y 90; GEMCITABINE; HRS7 7 ETHYL 10 HYDROXYCAMPTOTHECIN ANTIBODY CONJUGATE; IMMU 132; IMMU 133; IMMU 134; IRINOTECAN; MUCIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VELTUZUMAB 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; VELTUZUMAB 7 ETHYL 10 HYDROXYCAMPTOTHECIN ANTIBODY CONJUGATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; DRUG UPTAKE; FEMALE; HYPERKERATOSIS; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTOXINS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 79958751015     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0115     Document Type: Article

References (50)

1. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46 Suppl 1:115S-27S.
2. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 2010;51:1155-62.
3. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv 2011;8:26-44.
4. 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30:6-10.
5. Du Y, Honeychurch J, Cragg MS, Bayne M, Glennie MJ, Johnson PW, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004;103:1485-94. (Pubitemid 38168666)
6. Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo) 2005;46:241-8. (Pubitemid 41190661)
7. Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res 2006;47:183-96. (Pubitemid 44034037)
8. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85.
9. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009;9:982-1004.
10. Burris HA, 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
11. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13-21. (Pubitemid 36173256)
12. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006;16:2-9. (Pubitemid 41832311)
13. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002;94:1320-31.
14. DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell RT, Kukis DL, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 1997;80:2583-90. (Pubitemid 28009515)
15. Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit Rev Oncol Hematol 2002;43:57-62. (Pubitemid 34722787)
16. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52. (Pubitemid 38018066)
17. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, et al. High-dose radioimmunotherapy combined with fixed, lowdose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005;11:5920-7.
18. 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 2005;46:620-33.
19. Shibata S, Raubitschek A, Leong L, Koczywas M, Williams L, Zhan J, et al. A phase I study of a combination of yttrium-90-labeled anticarcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 2009;15:2935-41.
20. 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer 2004;109:618-26.
21. 90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929S-37S.
22. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34:1500-8. (Pubitemid 28446329)
23. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011 Mar 3 [Epub ahead of print].
24. 90Y-clivatuzumab tetraxetan (humanized anti-pancreatic mucin antibody, hPAM4): a phase I dose escalation trial. Clin Cancer Res. In press 2011.
25. Pennington K, Guarion MJ, Serafini AN, Rocah-Lima C, Suppiah K, Schneider CJ, et al. Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer. J Clin Oncol 2009;27:231 Abstract 4620.
26. Ocean AJ, Guarino MJ, Pennington KL, Montero AJ, Bekaii-Saab T, Gulec SA, et al. Fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) is active in advanced pancreatic cancer (APC). J Clin Oncol 2011;29:Abstract 240.
27. Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res 1995;55:1105-10.
28. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51:747-55.
29. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003;44:77-84. (Pubitemid 36077716)
30. 90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009;50:2008-16.
31. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.
32. Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000;60:4206-10. (Pubitemid 30636606)
33. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
34. 131I-tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396-402.
35. 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008;14:6154-60.
36. 131 KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 2009;9:66.
37. 90Yttriumlabeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000;6:3095-102.
38. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997;15:1518-28. (Pubitemid 27167388)
39. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94. (Pubitemid 32751614)
40. Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008;51:6916-26.
41. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008;7:280-5. (Pubitemid 351302522)
42. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008;99:1290-5.
43. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008;112:830-5.
44. Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 2009;50:444-53.
45. Kletting P, Meyer C, Reske SN, Glatting G. Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling. Cancer Biother Radiopharm 2010;25:279-87.
46. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006;66:10048-56. (Pubitemid 44672058)
47. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 2008;14: 1888-96. (Pubitemid 351469476)
48. Guo Z, Wheler JJ, Naing A, Mani S, Goel S, Mulcahy M, et al. Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I, first-in-human, dose-escalation study. J Clin Oncol 2008;26:Abstract 2556.
49. Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 2010;16:5058-66.
50. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.